Glaucoma lecturer likens preserved drops to processed foods-neither is the healthiest ideal

Article

 

San Diego-“Trying to reduce BAK load is the right thing to do overall,” said Michael Chaglasian, OD, associate professor at Illinois College of Optometry and chief of staff at the Illinois Eye Institute. In his lecture yesterday morning, Preservative vs. Preservative Free Medication in Glaucoma, Dr. Chaglasian made a strong case that there are several deleterious effects of BAK, which should prompt practitioners to avoid them in many cases.

Dr. Chaglasian admitted he wasn’t always concerned about BAK. In fact, he said he didn’t used to pay much attention to ocular surface disease in his glaucoma patients. But, the Dry Eye Work Shop (DEWS) report in 2007 was a wake-up moment for him. The DEWS conclusion that the elimination of preservatives from OTC lubricants was a huge leap forward in ocular surface care made him think more seriously about the effects of preservatives in the glaucoma meds he prescribed. He wondered, “If preservatives play such a big role in ocular surface health, how might they be affecting my glaucoma patients, who use them long term?”

Since effects of preserved drops in glaucoma treatment tend to be subtle and build up over time, they are often overlooked. “But they can have a significant impact,” he said. BAK has several effects on the ocular surface, including:

  • Decreased epithelial cell integrity

  • Increased conjunctival inflammatory cells

  • Loss of goblet cells

  • Reduced tear function

  • Reduced TBUT

Beyond it’s relationship to ocular surface disease, BAK is associated with filtration bleb failure in trabeculectomy patients and inflammatory cell infiltration in the trabecular meshwork. Furthermore, new research also suggests that BAK affects the eyelid muscles, causing incomplete blink and lagophthalmus in animal models.

Dr. Chaglasian recommended that doctors consider the following factors when prescribing topical medications as these contribute to preservative toxicity:

  • Concentration

  • Frequency and duration of use

  • Tear production and clearance

  • Contact lens use

  • Number and type of concurrent meds

  • Type of preservative

Not every patient needs to be treated with BAK-free drops but, he said, clinicians need an evaluation and workup to avoid harming at-risk patients.ODT

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.